D
BioCryst Pharmaceuticals, Inc.
BCRX
$6.88
-$0.45-6.14%
D
Sell
7/15/2024Upgraded
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded to D- from E+ on 7/15/2024 due to an increase in the total return index and volatility index.
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded to D- from E+ on 7/15/2024 due to an increase in the total return index and volatility index.
E
Sell
6/28/2024Downgrade
BioCryst Pharmaceuticals, Inc. (BCRX) was downgraded to E+ from D- on 6/28/2024 due to a decline in the volatility index.
BioCryst Pharmaceuticals, Inc. (BCRX) was downgraded to E+ from D- on 6/28/2024 due to a decline in the volatility index.
D
Sell
6/13/2024Upgraded
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded to D- from E+ on 6/13/2024 due to an increase in the volatility index and total return index.
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded to D- from E+ on 6/13/2024 due to an increase in the volatility index and total return index.
E
Sell
5/28/2024Downgrade
BioCryst Pharmaceuticals, Inc. (BCRX) was downgraded to E+ from D- on 5/28/2024 due to a decline in the volatility index and valuation index.
BioCryst Pharmaceuticals, Inc. (BCRX) was downgraded to E+ from D- on 5/28/2024 due to a decline in the volatility index and valuation index.
D
Sell
5/9/2024Upgraded
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded to D- from E+ on 5/9/2024 due to a substantial increase in the growth index and solvency index. EBIT increased 61.61% from -$37.74M to -$14.49M, earnings per share increased from -$0.3065 to -$0.1717, and the quick ratio increased from 2.97 to 3.31.
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded to D- from E+ on 5/9/2024 due to a substantial increase in the growth index and solvency index. EBIT increased 61.61% from -$37.74M to -$14.49M, earnings per share increased from -$0.3065 to -$0.1717, and the quick ratio increased from 2.97 to 3.31.
E
Sell
4/1/2024Downgrade
BioCryst Pharmaceuticals, Inc. (BCRX) was downgraded to E+ from D- on 4/1/2024 due to a noticeable decline in the solvency index and total return index.
BioCryst Pharmaceuticals, Inc. (BCRX) was downgraded to E+ from D- on 4/1/2024 due to a noticeable decline in the solvency index and total return index.
D
Sell
3/14/2024Upgraded
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded to D- from E+ on 3/14/2024 due to an increase in the volatility index and total return index.
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded to D- from E+ on 3/14/2024 due to an increase in the volatility index and total return index.
E
Sell
2/28/2024Downgrade
BioCryst Pharmaceuticals, Inc. (BCRX) was downgraded to E+ from D- on 2/28/2024 due to a decline in the growth index, volatility index and valuation index. EBIT declined 229.59% from -$11.92M to -$39.29M, and earnings per share declined from -$0.1906 to -$0.3065.
BioCryst Pharmaceuticals, Inc. (BCRX) was downgraded to E+ from D- on 2/28/2024 due to a decline in the growth index, volatility index and valuation index. EBIT declined 229.59% from -$11.92M to -$39.29M, and earnings per share declined from -$0.1906 to -$0.3065.
D
Sell
2/22/2024Upgraded
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded to D- from E+ on 2/22/2024 due to an increase in the volatility index and total return index.
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded to D- from E+ on 2/22/2024 due to an increase in the volatility index and total return index.
E
Sell
2/6/2024Downgrade
BioCryst Pharmaceuticals, Inc. (BCRX) was downgraded to E+ from D- on 2/6/2024 due to a decline in the volatility index, total return index and growth index.
BioCryst Pharmaceuticals, Inc. (BCRX) was downgraded to E+ from D- on 2/6/2024 due to a decline in the volatility index, total return index and growth index.
D
Sell
1/22/2024Upgraded
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded to D- from E+ on 1/22/2024 due to an increase in the volatility index.
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded to D- from E+ on 1/22/2024 due to an increase in the volatility index.
E
Sell
1/4/2024Downgrade
BioCryst Pharmaceuticals, Inc. (BCRX) was downgraded to E+ from D- on 1/4/2024 due to a decline in the total return index and volatility index.
BioCryst Pharmaceuticals, Inc. (BCRX) was downgraded to E+ from D- on 1/4/2024 due to a decline in the total return index and volatility index.
D
Sell
12/13/2023Upgraded
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded to D- from E+ on 12/13/2023 due to an increase in the volatility index.
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded to D- from E+ on 12/13/2023 due to an increase in the volatility index.
E
Sell
11/28/2023Downgrade
BioCryst Pharmaceuticals, Inc. (BCRX) was downgraded to E+ from D- on 11/28/2023 due to a decline in the volatility index and total return index.
BioCryst Pharmaceuticals, Inc. (BCRX) was downgraded to E+ from D- on 11/28/2023 due to a decline in the volatility index and total return index.
D
Sell
11/10/2023Upgraded
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded to D- from E+ on 11/10/2023 due to a noticeable increase in the growth index and volatility index. Earnings per share increased from -$0.4 to -$0.1906, EBIT increased 42.42% from -$20.7M to -$11.92M, and total revenue increased 5.15% from $82.49M to $86.74M.
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded to D- from E+ on 11/10/2023 due to a noticeable increase in the growth index and volatility index. Earnings per share increased from -$0.4 to -$0.1906, EBIT increased 42.42% from -$20.7M to -$11.92M, and total revenue increased 5.15% from $82.49M to $86.74M.
E
Sell
11/8/2023Downgrade
BioCryst Pharmaceuticals, Inc. (BCRX) was downgraded to E+ from D- on 11/8/2023 due to a noticeable decline in the total return index, volatility index and growth index. Earnings per share declined from -$0.2829 to -$0.4.
BioCryst Pharmaceuticals, Inc. (BCRX) was downgraded to E+ from D- on 11/8/2023 due to a noticeable decline in the total return index, volatility index and growth index. Earnings per share declined from -$0.2829 to -$0.4.
D
Sell
3/14/2023Downgrade
BioCryst Pharmaceuticals, Inc. (BCRX) was downgraded to D- from D+ on 3/14/2023 due to a decline in the growth index. EBIT declined 165.47% from -$17.45M to -$46.31M, and earnings per share declined from -$0.2284 to -$0.3827.
BioCryst Pharmaceuticals, Inc. (BCRX) was downgraded to D- from D+ on 3/14/2023 due to a decline in the growth index. EBIT declined 165.47% from -$17.45M to -$46.31M, and earnings per share declined from -$0.2284 to -$0.3827.
D
Sell
2/9/2023Upgraded
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded to D+ from D- on 02/09/2023.
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded to D+ from D- on 02/09/2023.
D
Sell
2/8/2023Downgrade
BioCryst Pharmaceuticals, Inc. (BCRX) was downgraded to D- from D+ on 2/8/2023 due to a noticeable decline in the growth index, total return index and valuation index. Operating cash flow declined 16.89% from -$27.76M to -$32.44M.
BioCryst Pharmaceuticals, Inc. (BCRX) was downgraded to D- from D+ on 2/8/2023 due to a noticeable decline in the growth index, total return index and valuation index. Operating cash flow declined 16.89% from -$27.76M to -$32.44M.
D
Sell
8/8/2022Upgraded
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded to D+ from D on 8/8/2022 due to a major increase in the growth index, total return index and volatility index. Operating cash flow increased 64.32% from -$77.8M to -$27.76M, total revenue increased 31.27% from $49.92M to $65.53M, and EBIT increased 30.5% from -$49.96M to -$34.72M.
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded to D+ from D on 8/8/2022 due to a major increase in the growth index, total return index and volatility index. Operating cash flow increased 64.32% from -$77.8M to -$27.76M, total revenue increased 31.27% from $49.92M to $65.53M, and EBIT increased 30.5% from -$49.96M to -$34.72M.
D
Sell
6/10/2022Downgrade
BioCryst Pharmaceuticals, Inc. (BCRX) was downgraded to D from D+ on 6/10/2022 due to a decline in the total return index and valuation index.
BioCryst Pharmaceuticals, Inc. (BCRX) was downgraded to D from D+ on 6/10/2022 due to a decline in the total return index and valuation index.
D
Sell
5/18/2022Upgraded
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded to D+ from D- on 5/18/2022 due to an increase in the total return index and volatility index.
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded to D+ from D- on 5/18/2022 due to an increase in the total return index and volatility index.
D
Sell
5/13/2022Downgrade
BioCryst Pharmaceuticals, Inc. (BCRX) was downgraded to D- from D+ on 5/13/2022 due to a large decline in the total return index, growth index and volatility index. Earnings per share declined from -$0.0978 to -$0.4013, and operating cash flow declined 139.69% from -$32.46M to -$77.8M.
BioCryst Pharmaceuticals, Inc. (BCRX) was downgraded to D- from D+ on 5/13/2022 due to a large decline in the total return index, growth index and volatility index. Earnings per share declined from -$0.0978 to -$0.4013, and operating cash flow declined 139.69% from -$32.46M to -$77.8M.
D
Sell
5/4/2022Upgraded
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded to D+ from D- on 5/4/2022 due to a noticeable increase in the total return index.
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded to D+ from D- on 5/4/2022 due to a noticeable increase in the total return index.
D
Sell
5/1/2022Downgrade
BioCryst Pharmaceuticals, Inc. (BCRX) was downgraded to D- from D+ on 5/1/2022 due to a large decline in the total return index.
BioCryst Pharmaceuticals, Inc. (BCRX) was downgraded to D- from D+ on 5/1/2022 due to a large decline in the total return index.
D
Sell
4/21/2022Upgraded
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded to D+ from D- on 4/21/2022 due to an increase in the total return index.
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded to D+ from D- on 4/21/2022 due to an increase in the total return index.
D
Sell
4/20/2022Downgrade
BioCryst Pharmaceuticals, Inc. (BCRX) was downgraded to D- from D+ on 4/20/2022 due to a decline in the volatility index and valuation index.
BioCryst Pharmaceuticals, Inc. (BCRX) was downgraded to D- from D+ on 4/20/2022 due to a decline in the volatility index and valuation index.
D
Sell
11/9/2021Upgraded
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded to D+ from D- on 11/09/2021.
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded to D+ from D- on 11/09/2021.
D
Sell
11/8/2021Downgrade
BioCryst Pharmaceuticals, Inc. (BCRX) was downgraded to D- from D+ on 11/8/2021 due to a substantial decline in the total return index and solvency index. Debt to equity increased from -2.78 to -2.08, and the quick ratio declined from 2.13 to 1.69.
BioCryst Pharmaceuticals, Inc. (BCRX) was downgraded to D- from D+ on 11/8/2021 due to a substantial decline in the total return index and solvency index. Debt to equity increased from -2.78 to -2.08, and the quick ratio declined from 2.13 to 1.69.
D
Sell
3/3/2021Upgraded
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded to D+ from D on 3/3/2021 due to a significant increase in the total return index, valuation index and volatility index.
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded to D+ from D on 3/3/2021 due to a significant increase in the total return index, valuation index and volatility index.
D
Sell
5/1/2020Upgraded
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded to D from D- on 5/1/2020 due to an increase in the solvency index and growth index. Total revenue increased 2,138.03% from $1.78M to $39.73M, EBIT increased 99.69% from -$35.1M to -$109, and the quick ratio increased from 0.88 to 1.72.
BioCryst Pharmaceuticals, Inc. (BCRX) was upgraded to D from D- on 5/1/2020 due to an increase in the solvency index and growth index. Total revenue increased 2,138.03% from $1.78M to $39.73M, EBIT increased 99.69% from -$35.1M to -$109, and the quick ratio increased from 0.88 to 1.72.
D
Sell
3/11/2016Downgrade
BioCryst Pharmaceuticals, Inc. (BCRX) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and solvency index. Debt to equity increased from 0.47 to 0.63, and the quick ratio declined from 1.21 to 0.9.
BioCryst Pharmaceuticals, Inc. (BCRX) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and solvency index. Debt to equity increased from 0.47 to 0.63, and the quick ratio declined from 1.21 to 0.9.
NASDAQ
04/04/2025 12:58PM Eastern
Quotes delayed
